Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (GLTO)

Q: What does CUSIP 36322Q107 represent in this 13F holders report?

CUSIP 36322Q107 is the security identifier for GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value used to aggregate holder disclosures.

Q: How many institutions held GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value in Q3 2021?

25 institutional investors reported GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value for Q3 2021. Use the holders table for investor-level position and value details.

CUSIP: 36322Q107

Q3 2021 13F Holders as of 30 Sep 2021

Security type / class: Equity / American Depository Shares, each of which represent twenty ordinary shares, no par value
Total 13F shares: 10,398,274
Total 13F value: $37,206,000
Share change: -973,528
SEC-reported price per share: $3.59
Number of holders: 25
Value change: -$5,044,237
Number of buys: 15
Number of sells: 12
Shares outstanding: 7,500,000

Security key

36322Q107

Report period

Q3 2021

Institutions

Top holders

GLTO full security history Ownership snapshot Full 13F holder table Chemomab Therapeutics Ltd. SEC filings Chemomab Therapeutics Ltd. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

ORBIMED ADVISORS LLC

Disclosed value leader

ORBIMED ADVISORS LLC

Comparable rows

0/15

Latest evidence

30 Jun 2021

13F Highest disclosed value: $69,737,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC has the largest disclosed position value at $69.74M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.

Disclosed position value Top 5

ORBIMED ADVISORS LLC $69.74M

Novo Holdings A/S $12.64M

Cormorant Asset Management, LP $8.87M

Janus Henderson Group Ltd. $6.41M

Ikarian Capital, LLC $5.53M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
ORBIMED ADVISORS LLC	13F Company 13F	— mixed-class rows	$69,737,000 6,669,111 shares mixed-class rows	—	30 Jun 2021
Novo Holdings A/S	13F Company 13F	— denominator unverified	$12,639,000 2,497,791 shares	—	30 Jun 2021
Cormorant Asset Management, LP	13F Company 13F	— denominator unverified	$8,874,000 1,753,839 shares	—	30 Jun 2021
Janus Henderson Group Ltd.	13F Company 13F	— denominator unverified	$6,406,000 1,299,504 shares	—	30 Jun 2021
Ikarian Capital, LLC	13F Company 13F	— denominator unverified	$5,526,000 290,534 shares	—	30 Jun 2021
Soleus Capital Management, L.P.	13F Company 13F	— denominator unverified	$2,723,000 538,152 shares	—	30 Jun 2021

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

10,398,274

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2021 vs Q2 2021 Across Filers

Q2 2021 holders

Q3 2021 holders

Holder diff

Investor	Q2 2021 Shares	Q3 2021 Shares	Share Diff	Share Chg %	Q2 2021 value	Q3 2021 value	Value change	Value Chg %